Publications

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial

Mayne K. et al, (2024), Nephrology Dialysis Transplantation

Patient and public involvement and engagement in the ASCEND PLUS Trial: Reflections from the design of a streamlined and decentralised clinical trial

WIJESURENDRA R. et al, (2024), Trials

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial

Mayne K. and HERRINGTON W., (2024), American Society of Nephrology. Clinical Journal

Effect of Fenofibrate on Progression of Diabetic Retinopathy.

Preiss D. et al, (2024), NEJM evidence, EVIDoa2400179 - EVIDoa2400179

Association of daily steps with incident non-alcoholic fatty liver disease: Evidence from the UK Biobank cohort

Fulda ES. et al, (2024)

Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis.

Cholesterol Treatment Trialists’ (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk None. and Cholesterol Treatment Trialists’ (CTT) Collaboration None., (2024), Lancet Diabetes Endocrinol, 12, 306 - 319

Design, recruitment, and baseline characteristics of the LENS trial

PREISS D. et al, (2024), Diabetic Medicine

Diabetic retinopathy and quality of life: A systematic review and Meta-analysis

Zayed M. et al, (2024), JAMA Ophthalmology

Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease

Mayne K. et al, (2023), Journal of the American Society of Nephrology

Impact of Primary Kidney Disease on the Effects of Empagliflozin in Patients with Chronic Kidney Disease: Secondary Analyses of the EMPA-KIDNEY trial

Judge P. et al, (2023), Lancet Diabetes and Endocrinology

Quality of care for secondary cardiovascular disease prevention in 2009- 2017: population-wide cohort study of antiplatelet therapy use in Scotland

PREISS D. et al, (2023), BMJ Quality and Safety

Intima-media thickness at the near or far wall of the common carotid artery in cardiovascular risk assessment.

Seekircher L. et al, (2023), Eur Heart J Open, 3

Late-Breaking Science Abstracts and Featured Science Abstracts From the American Heart Association's Scientific Sessions 2022 and Late-Breaking Abstracts in Resuscitation Science From the Resuscitation Science Symposium 2022.

(2022), Circulation, 146, e569 - e605

Empagliflozin in Patients with Chronic Kidney Disease

HERRINGTON W. et al, (2022), New England Journal of Medicine

Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials

HERRINGTON W. et al, (2022), The Lancet

Population-wide cohort study of statin use for the secondary cardiovascular disease prevention in Scotland in 2009-2017

PREISS D. et al, (2022), Heart

Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.

Cholesterol Treatment Trialists' Collaboration None., (2022), Lancet (London, England), 400, 832 - 845

Individual participant data meta-analysis of muscle symptoms in large-scale randomised double-blind trials of statin therapy

BAIGENT C. et al, (2022), The Lancet

Harmonization of large-scale, heterogeneous individual participant adverse event data from randomized trials of statin therapy

EMBERSON J. et al, (2022), Clinical Trials

Beyond Ten-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease

Kohli-Lynch CN. et al, (2022), Circulation

Cookies on this website

Publications